Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
about
Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirusInhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring systemAntiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early regionA standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patientsThe use of antiviral drugs during the neonatal periodEmerging therapies for herpes viral infections (types 1 - 8).Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplificationHigh dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.The Cys607-->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients.Antimicrobial strategies in the care of organ transplant recipientsSingle amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovPoint mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents.Long term therapy of cytomegalovirus retinitis with ganciclovir in a child with acquired immunodeficiency syndrome.Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures.Retinal disease associated with AIDS."The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection.Thiazolo[4,5-d]pyrimidines. Part II. Synthesis and anti-human cytomegalovirus activity in vitro of certain acyclonucleosides and acyclonucleotides derived from the guanine analogue 5-aminothiazolo[4,5-d]pyrimidine-2,7(3H,6H)-dione.A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome.Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.Cidofovir in the treatment of cytomegaloviral disease.Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.
P2860
Q28344048-352B076E-48EB-40BC-AB43-F12BF42845DEQ28368061-81DDFA0E-C2F8-4323-BA99-DD54A8570DB7Q28378352-B1501A5A-D188-4921-AAEB-B84889164A44Q33978966-C09E1210-8664-4B63-B347-D80CD786AEDCQ35227779-AD101F27-ED63-4CCA-9DFF-06CB5CE8AB19Q35789702-075939EC-2851-40F6-B4D2-2D50EE31FA7AQ35967376-0E8590D7-D853-4752-8AA7-51262B342EACQ37126781-9097BA64-2681-4FFF-871D-CFA348770A35Q37304750-A6E33A0E-DCE8-4795-8D8B-FDEFAD56F0AAQ38285782-9B6AFC09-76A6-4013-BA7E-EE201D5366F9Q39556801-7B8EF6D7-6382-488E-947E-4EC2934A8E0AQ39865375-4FB649DC-D616-46DC-9CFA-7122A546067FQ39873608-4A84D2DA-F576-4E26-B13E-5C9B46799DDBQ40062049-861C7F80-D97B-4D7A-9A3B-291B5E203828Q40142484-CD02100D-DB02-4939-93BB-B53E769CFFEEQ40215069-39E86A1D-8ACB-4E0B-B0E6-733F4FD06DF2Q40711240-8AF8AD50-4793-43ED-B973-B5B6B1646AE8Q40720231-8F8416EC-2C1C-4E2F-ACC4-5CD0064EF8F2Q40853845-6F829857-5A8C-4C48-94D8-7296DF43257DQ40883283-33E95A9A-0F98-45EA-A13E-DAC87D4E9D1DQ40983979-84BCD4EE-9AA5-49AF-9CBE-8D9FB82E4F1AQ41065948-BE4FB41E-1D9A-494D-87EA-7925F69E64C8Q42288776-6D55CD7A-7CBB-4338-9AB6-F4DBD0605231Q43733294-37F943CC-0A81-4D2B-80DD-5C7F23CDDDCDQ44570856-17F5FE8E-AFC2-40D2-95D1-3B90F2EC857EQ54115801-0FF94894-7F58-465B-82AF-46DEF59DC117Q54257052-F104EFA3-F5BE-4D6D-8034-CAA645E41C78
P2860
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Foscarnet therapy for ganciclo ...... tinitis in patients with AIDS.
@en
Foscarnet therapy for ganciclo ...... tinitis in patients with AIDS.
@nl
type
label
Foscarnet therapy for ganciclo ...... tinitis in patients with AIDS.
@en
Foscarnet therapy for ganciclo ...... tinitis in patients with AIDS.
@nl
prefLabel
Foscarnet therapy for ganciclo ...... tinitis in patients with AIDS.
@en
Foscarnet therapy for ganciclo ...... tinitis in patients with AIDS.
@nl
P2093
P356
P1476
Foscarnet therapy for ganciclo ...... tinitis in patients with AIDS.
@en
P2093
Feinberg J
Jacobson MA
O'Donnell JJ
Whitmore PV
P304
P356
10.1093/INFDIS/163.6.1348
P407
P577
1991-06-01T00:00:00Z